Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 01, 2022 7:57pm EDT
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress Jun 04, 2022 9:00am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 03, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 06, 2022 4:01pm EDT
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress May 05, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 29, 2022 4:01pm EDT
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022 Apr 28, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 22, 2022 4:01pm EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 08, 2022 4:01pm EDT
